Sometimes a paper is way above my head in some ways - and this is one. Nonetheless, it is of considerable interest that it describes a fundamental reason for T3 being the active hormone. It also explains why a genetic mutation can make T3 considerably less effective and is a basis for one form of Resistance to Thyroid Hormone.
Obviously this is rare, probably genuinely so, but the mere fact that it exists should be absorbed by all endocrinologists to be brought to the fore before dismissing the patient in front of them. Oddities can and do occur and must not be missed and ignored simply because they are infrequent.
J Clin Endocrinol Metab. 2019 Feb 28. pii: jc.2018-02794. doi: 10.1210/jc.2018-02794. [Epub ahead of print]
Insight into molecular determinants of T3 vs. T4 recognition from mutations in thyroid hormone receptor alpha and beta.
Wejaphikul K1,2, Groeneweg S1, Hilhorst-Hofstee Y3, Chatterjee VK4, Peeters RP1, Meima ME1, Visser WE1.
Author information
1 Erasmus MC, Department of Internal Medicine, Academic Center for Thyroid diseases, Rotterdam, the Netherlands.
2 Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
3 Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
4 Wellcome-MRC Institute of Metabolic Science, University of Cambridge, United Kingdom.
Abstract
CONTEXT:
The two major forms of circulating thyroid hormones (THs) are tri-iodothyronine (T3) and tetra-iodothyronine (T4). T3 is regarded as the biologically active hormone since it binds to thyroid hormone receptors (TRs) with greater affinity than T4. However, it is currently unclear what structural mechanisms underlie this difference in affinity.
OBJECTIVE:
Prompted by the identification of a novel M256T mutation in a resistance to thyroid hormone alpha (RTHα) patient, we investigated Met256 in TRα1 and the corresponding residue (Met310) in TRβ1, residues previously predicted by crystallographic studies in discrimination of T3 versus T4.
METHODS:
Clinical characterization of the RTHα patient and molecular studies (in silico protein modeling, radioligand binding, transactivation and receptor-cofactor studies) were performed.
RESULTS:
Structural modeling of the TRα1-M256T mutant showed that distortion of the hydrophobic niche to accommodate the outer ring of ligand was more pronounced for T3 than T4, suggesting that this substitution has little impact on the affinity for T4. In agreement with the model, TRα1-M256T selectively reduced the affinity for T3. Also, unlike other naturally occurring TRα mutations, TRα1-M256T had a differential impact on T3- versus T4-dependent transcriptional activation. TRα1-M256A and TRβ1-M310T mutants exhibited similar discordance for T3 versus T4.
CONCLUSIONS:
Met256-TRα1/Met310-TRβ1 strongly potentiates the affinity of TRs for T3, thereby largely determining that T3 is the bioactive hormone rather than T4. These observations provide insight into the molecular basis for underlying the different affinity of TRs for T3 versus T4, delineating a fundamental principle of thyroid hormone signaling.
Copyright © 2019 Endocrine Society.
PMID: 30817817
DOI: 10.1210/jc.2018-02794